ESLA

Estrella

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 1

consensus rating "Strong Buy"

Net Income Plunges

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About ESLA

Estrella Immunopharma, Inc.

A preclinical-stage biopharmaceutical company developing T-cell therapies

Industry

Biological Technology

Established Date

01/06/2021

Listing Date

09/14/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.estrellabio.com

Security Type

Common stock

Office address

5858 Horton Street, Suite 370, Emeryville, California 94608

Business

Introduction

Estrella Immunopharma, Inc., was incorporated in Delaware on January 6, 2021. The Company is a preclinical stage biopharmaceutical company developing CD19 and CD22 targeted ARTEMIS T cell therapies with the ability to address the therapeutic challenges of patients with blood cancer and solid tumors. The company's mission is to harness the evolutionary power of the human immune system to transform the lives of cancer patients. To accomplish this mission, the company's lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The company is also developing EB104, which also utilizes Eureka's ARTEMIS technology, not only for CD19, but also for CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies.

Company Financials

EPS

ESLA has released its 2024 Q2 earnings. EPS was reported at -0.03, versus the expected 0.00, missing expectations. The chart below visualizes how ESLA has performed over recent quarters, highlighting trends in earnings surprises.